Juno Therapeutics Inc. (JUNO) 56.66 $JUNO
AstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:43PM CDT
AstraZeneca's (AZN) global biologics research and development arm, MedImmune, inked deals with Innate Pharma, Celgene and Juno related to its anti-PD-L1 immune checkpoint inhibitor, MEDI4736.
AZN: 71.79 (-1.34), JUNO: 56.66 (-1.06), CELG: 118.71 (+2.62)
Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors grappled with deals real and imagined, industry competition...
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), PRGO: 192.89 (-8.74), PFE: 35.27 (-0.09), CLDN: 13.68 (-0.26), MYL: 76.06 (+2.37), OREX: 7.36 (-0.08), JNJ: 101.08 (+0.62), NVO: 56.65 (+0.44), TNXP: 6.52 (-0.15), ALNY: 119.01 (+0.29), GILD: 103.69 (-1.52), SGEN: 37.14 (-0.36), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), SNY: 51.75 (-0.01), NBY: 0.63 (unch), XLRN: 33.29 (-0.95)
Juno and AstraZeneca team up in combo treatment for blood cancer
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 12:00PM CDT
AZN: 71.79 (-1.34), JUNO: 56.66 (-1.06)
MedImmune and Juno Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
GlobeNewswire - Thu Apr 23, 7:10AM CDT
MedImmune, the global biologics research and development arm of AstraZeneca, and Juno Therapeutics, Inc., a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today that they have entered into a new collaboration to conduct combination clinical trials in immuno-oncology with one of Juno's investigational CD19-directed chimeric antigen receptor (CAR) T cell candidates and MedImmune's investigational programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor, MEDI4736. Under the initial development plan, both companies will explore the safety, tolerability and preliminary efficacy of the combination therapy as a potential treatment for patients with non-Hodgkin lymphoma (NHL).
JUNO: 56.66 (-1.06)
Juno Therapeutics Gets Lift From Cancer Test Results
at Investor's Business Daily - Tue Apr 21, 1:57PM CDT
Juno Therapeutics' (JUNO) stock rebounded Tuesday as the company reported "highly encouraging" results from a clinical trial on pediatric patients with leukemia, after shares fell sharply Monday. Juno is developing cellular immunotherapies to treat...
BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
Juno CAR-T candidate delivers 91% complete remission in pediatric blood cancer
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 11:03AM CDT
JUNO: 56.66 (-1.06)
Juno Therapeutics' CAR T Cell Product Candidate JCAR017 Continues to Demonstrate Encouraging Outcomes in Pediatric Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia
GlobeNewswire - Tue Apr 21, 9:30AM CDT
Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today encouraging clinical responses in a Phase 1 study evaluating JCAR017 in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The results of this trial to date demonstrated that 91% of patients achieved a complete remission as documented by flow cytometry. Adverse events were consistent with what has been previously reported. JCAR017 is a chimeric antigen receptor (CAR) T cell product candidate subject to a licensing arrangement with Seattle Children's Research Institute. The results were presented in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, Pennsylvania.
JUNO: 56.66 (-1.06)
Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia
PR Newswire - Tue Apr 21, 9:30AM CDT
Seattle Children's announced today that 20 of 22 patients treated thus far in a clinical trial using genetically reprogrammed T cells to treat relapsed acute lymphoblastic leukemia (ALL) have achieved complete remission, confirmed by highly sensitive tests designed to detect minute amounts of cancer cells. The 20 patients who have achieved complete remission included children with very high tumor burdens as well as children who were diagnosed with ALL as infants.
JUNO: 56.66 (-1.06)
Why Shares of Juno Therapeutics Inc. and Kite Pharma Inc. Crashed Today
Alex Planes, The Motley Fool - Motley Fool - Mon Apr 20, 5:59PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biotech upstarts Juno Therapeutics and ...
ZIOP: 10.81 (-0.39), KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
AACR - Solid Tumour CAR-T Foray Lives Up To Its Low-Key Billing
EP Vantage - at Seeking Alpha - Mon Apr 20, 3:58PM CDT
For some time now solid tumours has been seen as the next big battleground for CAR-T therapy, but based on the underwhelming early data released yesterday at the AACR meeting the best that can be said is that the jury is still out. A very early...
KITE: 60.58 (-0.35), MRK: 57.60 (+0.09), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
Juno Therapeutics (JUNO) Stock Falls Today on Mediocre Solid Tumor Therapy Data
at The Street - Mon Apr 20, 11:30AM CDT
Shares of Juno Therapeutics (JUNO) were down in late morning trading Monday after so-called CAR-T cellular therapies for solid tumors showed mediocre results at a conference on Sunday.
JUNO: 56.66 (-1.06)
Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data
at The Street - Mon Apr 20, 9:22AM CDT
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
ZIOP: 10.81 (-0.39), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06)
Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors
at The Street - Sun Apr 19, 11:45AM CDT
The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.
KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
Biotech Stocks Technical Report -- Novavax, MannKind, Juno Therapeutics, Curis, and Ohr Pharma
PR Newswire - Thu Apr 16, 8:15AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRIS: 2.96 (-0.01), NVAX: 8.58 (-0.07), OHRP: 2.94 (+0.12), JUNO: 56.66 (-1.06), MNKD: 4.80 (-0.16)
Etsy, Virtu Price High As IPOs Finally Wake Up
at Investor's Business Daily - Wed Apr 15, 6:45PM CDT
The 2015 IPO market is finally starting to pick up the pace after a relatively sleepy start. Etsy (ETSY), an e-commerce site for handmade goods and vintage items, was one of three notable initial public offerings that priced high in their expected...
XBIT: 22.94 (-4.50), VIRT: 22.16 (-0.44), ADRO: 36.00 (-0.39), KITE: 60.58 (-0.35), PRTY: 21.03 (-0.02), CDTX: 15.10 (-0.05), JUNO: 56.66 (-1.06), ETSY: 25.58 (-0.04)
Biotech IPOs Ignite As Aduro Doubles On First Day
at Investor's Business Daily - Wed Apr 15, 12:57PM CDT
Aduro Biotech (ADRO) soared on its initial public offering, one of three biotech IPOs Wednesday. Aduro, a developer of cancer immunotherapy treatments, priced at 17 and opened at 32. It raised $119 million, pricing 7 million shares at 17. The stock...
XBIT: 22.94 (-4.50), JNJ: 101.08 (+0.62), VIRT: 22.16 (-0.44), ADRO: 36.00 (-0.39), CDTX: 15.10 (-0.05), ETSY: 25.58 (-0.04), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
Heat Biologics Is An Opportunity Among Soaring Immunotherapy Biotech Valuations
Sharon di Stefano - Seeking Alpha - Tue Apr 14, 8:20AM CDT
Vaccination, in medical terminology, is injection of a disease-causing microorganism that stimulates the immune system to fight against infection, using the body's own defense mechanisms. Vaccination has all but wiped out polio, tetanus, chicken pox...
HTBX: 6.89 (-0.71), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), CLLS: 32.61 (-0.07), SPPI: 6.10 (+0.07), JUNO: 56.66 (-1.06), BMY: 65.80 (-0.20)
MabVax Therapeutics - A Bargain For Dr. Frost But Is It A Smart Buy For You?
Greg Buch - at Seeking Alpha - Tue Apr 14, 6:52AM CDT
OPK: 14.83 (+0.17), JUNO: 56.66 (-1.06)
Immunotherapy: Unleashing The Immune System To Decimate Cancer
ARK Investment Management - at Seeking Alpha - Sat Apr 11, 2:51AM CDT
By James Bannon, Analyst: Genomics For more than a century, surgery and poison have been the antidotes to cancer. When tumors are discovered, doctors decide whether or not to remove them surgically. With or without surgery, doctors typically...
KITE: 60.58 (-0.35), MRK: 57.60 (+0.09), AMGN: 167.91 (-1.26), JUNO: 56.66 (-1.06), BMY: 65.80 (-0.20), NVS: 104.28 (-1.22)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 401.71 (-28.57), SPHS: 0.80 (-0.03), ADMS: 17.70 (-0.03), TKMR: 18.75 (-0.25), CBYL: 7.45 (-0.11), HPTX: 45.97 (-0.11), QURE: 26.09 (-0.28), SHPG: 255.11 (-0.26), SRPT: 13.42 (-0.24), HZNP: 31.75 (+0.97), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), ABBV: 66.07 (+1.82), CBMG: 29.51 (-1.85), ARNA: 4.49 (+0.05), EXEL: 3.08 (-0.02), ADXS: 23.34 (-0.27), PTLA: 38.51 (-0.85), BMY: 65.80 (-0.20), OCUL: 25.36 (-1.12), NVO: 56.65 (+0.44), DVA: 83.91 (+0.50), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ALXN: 180.08 (-4.50), NVS: 104.28 (-1.22)
AstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:43PM CDT
AstraZeneca's (AZN) global biologics research and development arm, MedImmune, inked deals with Innate Pharma, Celgene and Juno related to its anti-PD-L1 immune checkpoint inhibitor, MEDI4736.
AZN: 71.79 (-1.34), JUNO: 56.66 (-1.06), CELG: 118.71 (+2.62)
Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors grappled with deals real and imagined, industry competition...
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), PRGO: 192.89 (-8.74), PFE: 35.27 (-0.09), CLDN: 13.68 (-0.26), MYL: 76.06 (+2.37), OREX: 7.36 (-0.08), JNJ: 101.08 (+0.62), NVO: 56.65 (+0.44), TNXP: 6.52 (-0.15), ALNY: 119.01 (+0.29), GILD: 103.69 (-1.52), SGEN: 37.14 (-0.36), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), SNY: 51.75 (-0.01), NBY: 0.63 (unch), XLRN: 33.29 (-0.95)
Juno and AstraZeneca team up in combo treatment for blood cancer
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 12:00PM CDT
AZN: 71.79 (-1.34), JUNO: 56.66 (-1.06)
MedImmune and Juno Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
GlobeNewswire - Thu Apr 23, 7:10AM CDT
MedImmune, the global biologics research and development arm of AstraZeneca, and Juno Therapeutics, Inc., a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today that they have entered into a new collaboration to conduct combination clinical trials in immuno-oncology with one of Juno's investigational CD19-directed chimeric antigen receptor (CAR) T cell candidates and MedImmune's investigational programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor, MEDI4736. Under the initial development plan, both companies will explore the safety, tolerability and preliminary efficacy of the combination therapy as a potential treatment for patients with non-Hodgkin lymphoma (NHL).
JUNO: 56.66 (-1.06)
Juno Therapeutics Gets Lift From Cancer Test Results
at Investor's Business Daily - Tue Apr 21, 1:57PM CDT
Juno Therapeutics' (JUNO) stock rebounded Tuesday as the company reported "highly encouraging" results from a clinical trial on pediatric patients with leukemia, after shares fell sharply Monday. Juno is developing cellular immunotherapies to treat...
BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
Juno CAR-T candidate delivers 91% complete remission in pediatric blood cancer
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 11:03AM CDT
JUNO: 56.66 (-1.06)
Juno Therapeutics' CAR T Cell Product Candidate JCAR017 Continues to Demonstrate Encouraging Outcomes in Pediatric Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia
GlobeNewswire - Tue Apr 21, 9:30AM CDT
Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today encouraging clinical responses in a Phase 1 study evaluating JCAR017 in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The results of this trial to date demonstrated that 91% of patients achieved a complete remission as documented by flow cytometry. Adverse events were consistent with what has been previously reported. JCAR017 is a chimeric antigen receptor (CAR) T cell product candidate subject to a licensing arrangement with Seattle Children's Research Institute. The results were presented in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, Pennsylvania.
JUNO: 56.66 (-1.06)
Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia
PR Newswire - Tue Apr 21, 9:30AM CDT
Seattle Children's announced today that 20 of 22 patients treated thus far in a clinical trial using genetically reprogrammed T cells to treat relapsed acute lymphoblastic leukemia (ALL) have achieved complete remission, confirmed by highly sensitive tests designed to detect minute amounts of cancer cells. The 20 patients who have achieved complete remission included children with very high tumor burdens as well as children who were diagnosed with ALL as infants.
JUNO: 56.66 (-1.06)
Why Shares of Juno Therapeutics Inc. and Kite Pharma Inc. Crashed Today
Alex Planes, The Motley Fool - Motley Fool - Mon Apr 20, 5:59PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biotech upstarts Juno Therapeutics and ...
ZIOP: 10.81 (-0.39), KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
AACR - Solid Tumour CAR-T Foray Lives Up To Its Low-Key Billing
EP Vantage - at Seeking Alpha - Mon Apr 20, 3:58PM CDT
For some time now solid tumours has been seen as the next big battleground for CAR-T therapy, but based on the underwhelming early data released yesterday at the AACR meeting the best that can be said is that the jury is still out. A very early...
KITE: 60.58 (-0.35), MRK: 57.60 (+0.09), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
Juno Therapeutics (JUNO) Stock Falls Today on Mediocre Solid Tumor Therapy Data
at The Street - Mon Apr 20, 11:30AM CDT
Shares of Juno Therapeutics (JUNO) were down in late morning trading Monday after so-called CAR-T cellular therapies for solid tumors showed mediocre results at a conference on Sunday.
JUNO: 56.66 (-1.06)
Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data
at The Street - Mon Apr 20, 9:22AM CDT
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
ZIOP: 10.81 (-0.39), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06)
Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors
at The Street - Sun Apr 19, 11:45AM CDT
The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.
KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
Biotech Stocks Technical Report -- Novavax, MannKind, Juno Therapeutics, Curis, and Ohr Pharma
PR Newswire - Thu Apr 16, 8:15AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRIS: 2.96 (-0.01), NVAX: 8.58 (-0.07), OHRP: 2.94 (+0.12), JUNO: 56.66 (-1.06), MNKD: 4.80 (-0.16)
Etsy, Virtu Price High As IPOs Finally Wake Up
at Investor's Business Daily - Wed Apr 15, 6:45PM CDT
The 2015 IPO market is finally starting to pick up the pace after a relatively sleepy start. Etsy (ETSY), an e-commerce site for handmade goods and vintage items, was one of three notable initial public offerings that priced high in their expected...
XBIT: 22.94 (-4.50), VIRT: 22.16 (-0.44), ADRO: 36.00 (-0.39), KITE: 60.58 (-0.35), PRTY: 21.03 (-0.02), CDTX: 15.10 (-0.05), JUNO: 56.66 (-1.06), ETSY: 25.58 (-0.04)
Biotech IPOs Ignite As Aduro Doubles On First Day
at Investor's Business Daily - Wed Apr 15, 12:57PM CDT
Aduro Biotech (ADRO) soared on its initial public offering, one of three biotech IPOs Wednesday. Aduro, a developer of cancer immunotherapy treatments, priced at 17 and opened at 32. It raised $119 million, pricing 7 million shares at 17. The stock...
XBIT: 22.94 (-4.50), JNJ: 101.08 (+0.62), VIRT: 22.16 (-0.44), ADRO: 36.00 (-0.39), CDTX: 15.10 (-0.05), ETSY: 25.58 (-0.04), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
Heat Biologics Is An Opportunity Among Soaring Immunotherapy Biotech Valuations
Sharon di Stefano - Seeking Alpha - Tue Apr 14, 8:20AM CDT
Vaccination, in medical terminology, is injection of a disease-causing microorganism that stimulates the immune system to fight against infection, using the body's own defense mechanisms. Vaccination has all but wiped out polio, tetanus, chicken pox...
HTBX: 6.89 (-0.71), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), CLLS: 32.61 (-0.07), SPPI: 6.10 (+0.07), JUNO: 56.66 (-1.06), BMY: 65.80 (-0.20)
MabVax Therapeutics - A Bargain For Dr. Frost But Is It A Smart Buy For You?
Greg Buch - at Seeking Alpha - Tue Apr 14, 6:52AM CDT
OPK: 14.83 (+0.17), JUNO: 56.66 (-1.06)
Immunotherapy: Unleashing The Immune System To Decimate Cancer
ARK Investment Management - at Seeking Alpha - Sat Apr 11, 2:51AM CDT
By James Bannon, Analyst: Genomics For more than a century, surgery and poison have been the antidotes to cancer. When tumors are discovered, doctors decide whether or not to remove them surgically. With or without surgery, doctors typically...
KITE: 60.58 (-0.35), MRK: 57.60 (+0.09), AMGN: 167.91 (-1.26), JUNO: 56.66 (-1.06), BMY: 65.80 (-0.20), NVS: 104.28 (-1.22)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 401.71 (-28.57), SPHS: 0.80 (-0.03), ADMS: 17.70 (-0.03), TKMR: 18.75 (-0.25), CBYL: 7.45 (-0.11), HPTX: 45.97 (-0.11), QURE: 26.09 (-0.28), SHPG: 255.11 (-0.26), SRPT: 13.42 (-0.24), HZNP: 31.75 (+0.97), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), ABBV: 66.07 (+1.82), CBMG: 29.51 (-1.85), ARNA: 4.49 (+0.05), EXEL: 3.08 (-0.02), ADXS: 23.34 (-0.27), PTLA: 38.51 (-0.85), BMY: 65.80 (-0.20), OCUL: 25.36 (-1.12), NVO: 56.65 (+0.44), DVA: 83.91 (+0.50), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ALXN: 180.08 (-4.50), NVS: 104.28 (-1.22)
